Journals / European Journal of Rheumatology / 2017 / Cilt: 4 - Sayı: 3

The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease

Pages
210–218
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we overview the endocannabinoid system, its role in pain, inflammation, and immune regulation, and highlight the emerging challenges and therapeutic hopes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pain is the most common manifestation of both acute and chronic inflammation that often challenges patients with rheumatic disease.
📊
Key Findings & Data:Simply, we attribute this to local joint changes of pH in joints, the formation of radicals, enhanced joint pressure, or cytokine release acting on local nerves to produce pain.
💡
Conclusion & Impact:In this review, we overview the endocannabinoid system, its role in pain, inflammation, and immune regulation, and highlight the emerging challenges and therapeutic hopes.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pain is the most common manifestation of both acute and chronic inflammation that often challenges patients with rheumatic disease. Simply, we attribute this to local joint changes of pH in joints, the formation of radicals, enhanced joint pressure, or cytokine release acting on local nerves to produce pain. However, there is a more complex interplay of interactions between cytokines, mediators of inflammation, and ion channels that influence the final immune response and our perception of pain. Endocannabinoids, a group of less well-known endogenous bioactive lipids, have such manifold immunomodulatory effects able to influence both inflammation and pain. In this review, we overview the endocannabinoid system, its role in pain, inflammation, and immune regulation, and highlight the emerging challenges and therapeutic hopes.

🔖

Cite This Article

MANOLİOS, N., BARRİE, N. (2022). The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. European Journal of Rheumatology, Cilt: 4 - Sayı: 3, 210–218. https://ajindex.com/articles/511712

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Mechoulam R, Devane WA, Breuer A, Zahalka J. A random walk through a cannabis field. Pharmacol Biochem Behav 1991
  2. [CrossRef] 2. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 2007
  3. [CrossRef] 3. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioural, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002
  4. [CrossRef] 4. Walker JM, Huang SM. Endocannabinoids in pain modulation. Prostaglandins Leukot Essent Fatty Acids 2002
  5. [CrossRef] 5. Richardson JD, Aanonsen L, Hargreaves KM. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998
  6. [CrossRef] 6. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998
  7. [CrossRef] 7. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Research 1998
  8. [CrossRef] 8. Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: specificity, recruitment and plasticity. Brain Res Rev 2009
  9. [CrossRef] 9. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001
  10. [CrossRef] 10. Fitzcharles MA, McDougall J, Ste-Marie PA, Padjen I. Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? Arthritis Rheum 2012
  11. [CrossRef] 11. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992
  12. [CrossRef] 12. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995
  13. [CrossRef] 13. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol 2000
  14. Schaible HG, Von Banchet GS, Boettger MK, Brauer R, Gajda M, Richter F, et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci 2010
  15. [CrossRef] 15. Starowicz K, Przewlocka B. Modulation of neuropathic-pain-related behavi